Optiscan Imaging Limited (AU:OIL) has released an update.
Optiscan Imaging Ltd has announced ethical clearance for an in vivo clinical study using their InVue™ precision surgery imaging platform for breast cancer treatment. The study will involve 50 patients to assess the platform’s real-time imaging capabilities during surgery, aiming to improve the accuracy of tumour removal. This development promises to enhance intraoperative decision-making, potentially transforming the standard of care in breast cancer surgeries.
For further insights into AU:OIL stock, check out TipRanks’ Stock Analysis page.
